Editas Medicine, Inc. (EDIT) jumped 35.15 percent to $3.09, rising $0.80 on Wednesday, after Custom Market Insights released a report projecting strong growth in the synthetic biology market.
The stock opened at $2.45 and traded between $2.44 and $3.10, with 4.68 million shares changing hands compared to an average of 2.46 million on the Nasdaq. Editas Medicine's 52-week range is $0.91 to $4.19.
Industry experts highlighted increasing demand for sustainable solutions such as biofuels, biodegradable plastics, and eco-friendly chemicals, alongside advances in gene editing and biotechnology that could drive innovation in healthcare, agriculture, and industrial applications.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.